Reducing Systemic Inflammation in People on Antiretroviral Therapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Human Immunodeficiency Virus (HIV) · Cardiovascular Risk Factor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CR CHUM, Montreal, Quebec, Canada
Contact: Study coordinator (Pascale Arlotto, STUDY NURSE) · pascale.arlotto.chum@ssss.gouv.qc.ca · 438-883-8933
Contact: Study coordinator (Madeleine Durand, SITE DOCTOR, MD) · RESTART.chum@ssss.gouv.qc.ca
Cecile Trambley (Sub-investigator)

Study leads

Madeleine Durand, MD MSc FRCPC
Principal Investigator
CR CHUM

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis

Abroad (travel likely)RecruitingPHASE3

Homabay County, Kenya · Thika, Kenya

Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans

HIV

Abroad (travel likely)Recruiting

Kalisizo, Uganda

Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults

HIV

Abroad (travel likely)Recruiting

Los Angeles, United States · Providence, United States

Evaluating Smoking Cessation Interventions for PWH in South Africa

Smoking Cessation · HIV · Comorbidities and Coexisting Conditions

Abroad (travel likely)RecruitingPHASE2, PHASE3

Soweto, South Africa